NCT06244316 - A Study to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution in Patients With Dry Eye Disease | Biotech Hunter

Enrollment

317

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions

Dry Eye Disease

Interventions

DRUG

rhNGF concentration 1

Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.

DRUG

rhNGF concentration 2

Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.

DRUG

Vehicle (Placebo solution)

Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.

Trial Locations (14)

19104

The Scheie Eye Institute, Philadelphia

20123

Ospedale S. Giuseppe Multimedica, Milan

30339

Eye Consultants of Atlanta, Atlanta

33437

Sibia Eye Institute, Boynton Beach

37217

Toyos Clinic, Nashville

38119

Total Eye Care PA, Memphis

80907

Vision Institute - Fontanero St, Colorado Springs

85224

Arizona Eye Center, Chandler

90505

East West Eye Institute, Torrance

98124

Azienda Ospedaliera Universitaria Policlinico G Martino, Messina

02116

New England Eye Center - Boston, Boston

07801

Eye Associates of North Jersey, Dover

00128

Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Roma

00161

Azienda Ospedaliero Universitario Policlinicol Umberto I, Roma

All Listed Sponsors

lead

Dompé Farmaceutici S.p.A

INDUSTRY